Although TP53 mutations are less frequent in WM compared to other B-cell lymphomas, emerging evidence suggests that their presence may contribute to disease progression and therapeutic response, particularly in cases that undergo transformation into DLBCL [28,29,30,31]. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.